Cargando…

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide

BACKGROUND: In metastatic castration-resistant prostate cancer (mCRPC), assessing treatment response and bone lesions with technetium-99m is limited by image resolution and subjectivity. We evaluated bone scan lesion area (BSLA), a quantitative imaging assessment of response in patients with mCRPC r...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrylak, D.P., Vaishampayan, U.N., Patel, K.R., Higano, C.S., Albany, C., Dawson, N.A., Mehlhaff, B.A., Quinn, D.I., Nordquist, L.T., Wagner, V.J., Siegel, J., Trandafir, L., Sartor, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985394/
https://www.ncbi.nlm.nih.gov/pubmed/33744812
http://dx.doi.org/10.1016/j.esmoop.2021.100082
_version_ 1783668237965197312
author Petrylak, D.P.
Vaishampayan, U.N.
Patel, K.R.
Higano, C.S.
Albany, C.
Dawson, N.A.
Mehlhaff, B.A.
Quinn, D.I.
Nordquist, L.T.
Wagner, V.J.
Siegel, J.
Trandafir, L.
Sartor, O.
author_facet Petrylak, D.P.
Vaishampayan, U.N.
Patel, K.R.
Higano, C.S.
Albany, C.
Dawson, N.A.
Mehlhaff, B.A.
Quinn, D.I.
Nordquist, L.T.
Wagner, V.J.
Siegel, J.
Trandafir, L.
Sartor, O.
author_sort Petrylak, D.P.
collection PubMed
description BACKGROUND: In metastatic castration-resistant prostate cancer (mCRPC), assessing treatment response and bone lesions with technetium-99m is limited by image resolution and subjectivity. We evaluated bone scan lesion area (BSLA), a quantitative imaging assessment of response in patients with mCRPC receiving radium-223 alone or in combination with androgen receptor pathway inhibitors (abiraterone/prednisone or enzalutamide). PATIENTS AND METHODS: This randomized, non-comparative phase IIa three-arm trial (NCT02034552) evaluated technetium-99m-based BSLA response rate (RR), safety, radiologic progression-free survival (rPFS), and time to first symptomatic skeletal event (SSE) in men with mCRPC and bone metastases receiving radium-223 with/without abiraterone/prednisone or enzalutamide. The primary endpoint was week 24 BSLA RR. RESULTS: Overall, 63 patients received treatment (abiraterone/prednisone combination, n = 22; enzalutamide combination, n = 22; radium-223 monotherapy, n = 19). Median treatment duration (first to last dose of any study treatment) was 12 months (abiraterone/prednisone combination), 10 months (enzalutamide combination), and 3 months (radium-223 monotherapy). Week 24 BSLA RR was 58% [80% confidence interval (CI) 41% to 74%; one-sided P < 0.0001; 11/19 patients] with abiraterone/prednisone combination, 50% (32% to 68%; one-sided P < 0.0001; 8/16 patients) with enzalutamide combination, and 22% (10% to 40%; one-sided P = 0.0109; 4/18 patients) with radium-223 monotherapy. Median rPFS was not evaluable for combination arms and 4 months (80% CI 4 to 12) for monotherapy. SSEs were reported in 32% of patients; median time to first SSE was not estimable. Fatigue and back pain were the most commonly reported treatment-emergent adverse events (TEAEs); more patients receiving combination therapy than monotherapy had TEAEs. Fractures were reported in 18% receiving abiraterone/prednisone, 32% receiving enzalutamide, and 11% receiving radium-223 monotherapy. Fracture rates were lower in patients taking bone health agents versus not taking bone health agents at baseline. CONCLUSIONS: Technetium-99m imaging BSLA may offer objective, quantifiable assessment of isotope uptake changes, and potentially treatment response, in patients with mCRPC and bone metastases treated with radium-223 alone or in combination with abiraterone/prednisone or enzalutamide. In this largely treatment-naive population, BSLA RR was numerically lower with radium-223 monotherapy versus combination therapy, indicating a limited role as first-line treatment. Use of radium-223 should follow evidence-based treatment guidelines and the licensed indication.
format Online
Article
Text
id pubmed-7985394
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-79853942021-03-25 A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide Petrylak, D.P. Vaishampayan, U.N. Patel, K.R. Higano, C.S. Albany, C. Dawson, N.A. Mehlhaff, B.A. Quinn, D.I. Nordquist, L.T. Wagner, V.J. Siegel, J. Trandafir, L. Sartor, O. ESMO Open Original Research BACKGROUND: In metastatic castration-resistant prostate cancer (mCRPC), assessing treatment response and bone lesions with technetium-99m is limited by image resolution and subjectivity. We evaluated bone scan lesion area (BSLA), a quantitative imaging assessment of response in patients with mCRPC receiving radium-223 alone or in combination with androgen receptor pathway inhibitors (abiraterone/prednisone or enzalutamide). PATIENTS AND METHODS: This randomized, non-comparative phase IIa three-arm trial (NCT02034552) evaluated technetium-99m-based BSLA response rate (RR), safety, radiologic progression-free survival (rPFS), and time to first symptomatic skeletal event (SSE) in men with mCRPC and bone metastases receiving radium-223 with/without abiraterone/prednisone or enzalutamide. The primary endpoint was week 24 BSLA RR. RESULTS: Overall, 63 patients received treatment (abiraterone/prednisone combination, n = 22; enzalutamide combination, n = 22; radium-223 monotherapy, n = 19). Median treatment duration (first to last dose of any study treatment) was 12 months (abiraterone/prednisone combination), 10 months (enzalutamide combination), and 3 months (radium-223 monotherapy). Week 24 BSLA RR was 58% [80% confidence interval (CI) 41% to 74%; one-sided P < 0.0001; 11/19 patients] with abiraterone/prednisone combination, 50% (32% to 68%; one-sided P < 0.0001; 8/16 patients) with enzalutamide combination, and 22% (10% to 40%; one-sided P = 0.0109; 4/18 patients) with radium-223 monotherapy. Median rPFS was not evaluable for combination arms and 4 months (80% CI 4 to 12) for monotherapy. SSEs were reported in 32% of patients; median time to first SSE was not estimable. Fatigue and back pain were the most commonly reported treatment-emergent adverse events (TEAEs); more patients receiving combination therapy than monotherapy had TEAEs. Fractures were reported in 18% receiving abiraterone/prednisone, 32% receiving enzalutamide, and 11% receiving radium-223 monotherapy. Fracture rates were lower in patients taking bone health agents versus not taking bone health agents at baseline. CONCLUSIONS: Technetium-99m imaging BSLA may offer objective, quantifiable assessment of isotope uptake changes, and potentially treatment response, in patients with mCRPC and bone metastases treated with radium-223 alone or in combination with abiraterone/prednisone or enzalutamide. In this largely treatment-naive population, BSLA RR was numerically lower with radium-223 monotherapy versus combination therapy, indicating a limited role as first-line treatment. Use of radium-223 should follow evidence-based treatment guidelines and the licensed indication. Elsevier 2021-03-19 /pmc/articles/PMC7985394/ /pubmed/33744812 http://dx.doi.org/10.1016/j.esmoop.2021.100082 Text en © 2021 Published by Elsevier Ltd on behalf of European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Petrylak, D.P.
Vaishampayan, U.N.
Patel, K.R.
Higano, C.S.
Albany, C.
Dawson, N.A.
Mehlhaff, B.A.
Quinn, D.I.
Nordquist, L.T.
Wagner, V.J.
Siegel, J.
Trandafir, L.
Sartor, O.
A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
title A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
title_full A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
title_fullStr A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
title_full_unstemmed A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
title_short A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
title_sort randomized phase iia study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mcrpc) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985394/
https://www.ncbi.nlm.nih.gov/pubmed/33744812
http://dx.doi.org/10.1016/j.esmoop.2021.100082
work_keys_str_mv AT petrylakdp arandomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT vaishampayanun arandomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT patelkr arandomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT higanocs arandomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT albanyc arandomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT dawsonna arandomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT mehlhaffba arandomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT quinndi arandomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT nordquistlt arandomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT wagnervj arandomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT siegelj arandomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT trandafirl arandomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT sartoro arandomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT petrylakdp randomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT vaishampayanun randomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT patelkr randomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT higanocs randomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT albanyc randomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT dawsonna randomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT mehlhaffba randomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT quinndi randomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT nordquistlt randomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT wagnervj randomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT siegelj randomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT trandafirl randomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide
AT sartoro randomizedphaseiiastudyofquantifiedbonescanresponseinpatientswithmetastaticcastrationresistantprostatecancermcrpctreatedwithradium223dichloridealoneorincombinationwithabirateroneacetateprednisoneorenzalutamide